MX2020006290A - Dinucleotidos ciclicos como agonistas de sting. - Google Patents

Dinucleotidos ciclicos como agonistas de sting.

Info

Publication number
MX2020006290A
MX2020006290A MX2020006290A MX2020006290A MX2020006290A MX 2020006290 A MX2020006290 A MX 2020006290A MX 2020006290 A MX2020006290 A MX 2020006290A MX 2020006290 A MX2020006290 A MX 2020006290A MX 2020006290 A MX2020006290 A MX 2020006290A
Authority
MX
Mexico
Prior art keywords
sub
sting agonists
cyclic dinucleotides
sting
compounds
Prior art date
Application number
MX2020006290A
Other languages
English (en)
Inventor
Guangyi Wang
Mark Richter
Leonid Beigelman
James Patrick Edwards
Stuart Emanuel
Santhosh Kumar Thatikonda
Peter J Connolly
Johannes Wilhelmus John Fitzgerald Thuring
Gilles Bignan
Sylvia Laquerre
Wim Gert Griet Schepens
Marcel Viellevoye
Minghong Zhong
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2020006290A publication Critical patent/MX2020006290A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen compuestos, composiciones y métodos para tratar enfermedades, síndromes o trastornos que se ven afectados por la modulación de STING; tales compuestos están representados por la Fórmula (I) de la siguiente manera: en donde B2, X2, 5 R2a, R2b, R2c, Z-M-Y, Y1- M1Z1, B1, X1, R1a, R1b, R1c son como se definen en la presente descripción.
MX2020006290A 2017-12-15 2018-12-14 Dinucleotidos ciclicos como agonistas de sting. MX2020006290A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762599111P 2017-12-15 2017-12-15
PCT/US2018/065677 WO2019118839A1 (en) 2017-12-15 2018-12-14 Cyclic dinucleotides as sting agonists

Publications (1)

Publication Number Publication Date
MX2020006290A true MX2020006290A (es) 2020-12-03

Family

ID=65003521

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006290A MX2020006290A (es) 2017-12-15 2018-12-14 Dinucleotidos ciclicos como agonistas de sting.

Country Status (11)

Country Link
US (1) US20210009630A1 (es)
EP (1) EP3724205B1 (es)
JP (1) JP7317014B2 (es)
KR (1) KR20200099178A (es)
CN (1) CN111712509A (es)
AU (1) AU2018386222B2 (es)
BR (1) BR112020010941A2 (es)
CA (1) CA3085337A1 (es)
ES (1) ES2927194T3 (es)
MX (1) MX2020006290A (es)
WO (1) WO2019118839A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CA3084582A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
EP4242212A3 (en) * 2018-03-23 2023-11-15 Takeda Pharmaceutical Company Limited Sting modulator compounds with sulfamate linkages, and methods of making and using
CA3093888A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
AU2019371206A1 (en) 2018-10-29 2021-05-27 Venenum Biodesign, LLC Novel sting agonists
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
JP2022538690A (ja) 2019-07-05 2022-09-05 タンボ・インコーポレイテッド トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
EP4134098A4 (en) 2020-04-10 2024-05-15 Ono Pharmaceutical Co CANCER THERAPY METHODS
EP4192506A1 (en) 2020-08-07 2023-06-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
TW202321275A (zh) * 2021-07-14 2023-06-01 美商健生生物科技公司 介白素—２３受體之雙環肽抑制劑

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470967A (en) * 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
EP1368458A2 (en) 2001-02-26 2003-12-10 Pharma Pacific Pty. Ltd. Interferon-alpha induced gene
CA3201163A1 (en) 2005-07-01 2007-01-11 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EA201170375A1 (ru) 2008-08-25 2012-03-30 Эмплиммьюн, Инк. Антагонисты pd-1 и способы их применения
HRP20240240T1 (hr) 2008-12-09 2024-04-26 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
WO2010108140A1 (en) * 2009-03-20 2010-09-23 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
KR20190133790A (ko) 2011-08-01 2019-12-03 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
MX363780B (es) * 2015-12-03 2019-04-03 Glaxosmithkline Ip Dev Ltd Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón.
BR112018068748B1 (pt) * 2016-03-18 2024-01-16 The Board Of Regents Of The University Of Texas System Composto dinucleotídeo cíclico, composição farmacêutica, e, uso de um composto
TW202030199A (zh) * 2018-07-17 2020-08-16 美商健生生物科技公司 作為ｓｔｉｎｇ促效劑之環狀二核苷酸

Also Published As

Publication number Publication date
RU2020123259A (ru) 2022-01-17
JP7317014B2 (ja) 2023-07-28
AU2018386222B2 (en) 2023-04-20
EP3724205A1 (en) 2020-10-21
WO2019118839A1 (en) 2019-06-20
KR20200099178A (ko) 2020-08-21
JP2021506803A (ja) 2021-02-22
EP3724205B1 (en) 2022-06-22
CN111712509A (zh) 2020-09-25
BR112020010941A2 (pt) 2020-11-17
ES2927194T3 (es) 2022-11-03
RU2020123259A3 (es) 2022-01-17
AU2018386222A1 (en) 2020-06-04
CA3085337A1 (en) 2019-06-20
US20210009630A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
MX2020006290A (es) Dinucleotidos ciclicos como agonistas de sting.
WO2018138685A3 (en) Cyclic dinucleotides as sting agonists
TN2019000192A1 (en) Pyrazole derivatives as malt1 inhibitors
MX2019006082A (es) Dinucleótidos cíclicos como agonistas de sting.
CR20210247A (es) Nuevos compuestos heterocíclicos
PH12021500014A1 (en) Fused ring compounds
WO2019090085A8 (en) Modulators of the integrated stress pathway
MX2021013193A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
PH12020552172A1 (en) Cyclic dinucleotides as sting agonists
CR20200373A (es) Compuestos
MX2021014350A (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.
MX2022003166A (es) Moduladores de il-17a y usos de los mismos.
MX2020013899A (es) Derivados de pirazol como inhibidores de malt1.
MY192425A (en) Polymorphs
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2017004645A (es) Derivados de benzotiofenilo como agonistas de gpr40 para el tratamiento de la diabetes tipo ii.
MX2020013699A (es) Derivados de pirazol como inhibidores de malt1.
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
CR20220004A (es) Nuevos compuestos heterocíclicos
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2020006370A (es) Pirazolopiridina-diamidas, su uso como insecticida y procesos para prepararlas.
MX2019000982A (es) Compuestos y composiciones y usos de los mismos.
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
MX367852B (es) Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii.